These favorable outcomes observed through the TCV approach in animal models of MS prompted subsequent exploration in clinical trials.502–504 An initial pilot trial encompassing eight patients diagnosed with RRMS or SPMS was conducted, where patients received TCV with irradiated T cells reactive to MBP. Here, MBP is linked to myeloid sarcoma.